A major immune escape mechanism involves inhibiting T-cell activation through interactions between PD-1 on T cells and PD-L1 on cancer cells [26,27], as well as between CTLA-4 on T cells and CD80/CD86 molecules on DCs [28], which are key targets of current immunotherapies. Here, CD274 is linked to cancer.